PARP‐1 inhibitors exacerbate DNA double‐strand breaks by impairing single‐strand DNA repair, ultimately promoting apoptosis in tumor cells.[189, 190, 191] Although BRCA mutations are present in only ≈20% of TNBC patients, several PARP inhibitors have received regulatory approval due to their clinical efficacy. The gene discussed is PARP1; the disease is neoplasm.